Acute Pharmacological Reduction of Plasma Free Fatty Acids ...

3 downloads 105 Views 283KB Size Report
po 4 h before, and 250 mg po 1 h before GHRH. The basal FFA levels. (799. 57 mmol/L) were reduced by acipimox throughout the whole test (values under 240.
0021-972X/97/$03.00/0 Journal of Clinical Endocrinology and Metabolism Copyright © 1997 by The Endocrine Society

Vol. 82, No. 9 Printed in U.S.A.

COMMENTS Acute Pharmacological Reduction of Plasma Free Fatty Acids Enhances the Growth Hormone (GH)-Releasing Hormone-Mediated GH Secretion in Patients with Cushing’s Syndrome* ALFONSO LEAL-CERRO, LUIS M. JIMENEZ, RICARDO ASTORGA, IGNACIO FERNANDEZ-LOPEZ, CARLOS DIEGUEZ, AND FELIPE F. CASANUEVA Division of Endocrinology, Hospital Virgen del Rocio (A.L.-C., R.A., L.M.J.), and Hospital Virgen de Valme (I.F.L.), Sevilla, Spain E-41013; and Endocrine Section, Complejo Hospitalario Universitario de Santiago Department of Medicine (F.F.C.) and Department of Physiology (C.D.), University of Santiago de Compostela, Spain E-15780 ABSTRACT In Cushing’s syndrome, GH secretion is blocked with all the stimuli tested. It has been reported that the acute pharmacological reduction of free fatty acids (FFA) leads to an enhancement of GH secretion in normal subjects and in pathological conditions associated with reduced GH secretion. To understand if the elevated FFA levels of hypercortisolism may be responsible for the altered GH secretion, 14 patients with active Cushing’s syndrome underwent 2 paired tests with 100 mg iv of GHRH on 2 different occasions. In one test, they were pretreated with placebo and in the other one, with acipimox 250 mg po 4 h before, and 250 mg po 1 h before GHRH. The basal FFA levels (799 6 57 mmol/L) were reduced by acipimox throughout the whole test (values under 240 6 28 mmol/L). In the placebo pretreated group, GHRH-induced GH secretion was

severely impeded, with a mean GH peak of 1.8 6 0.3 mg/L and area under the curve of 121.3 6 21.6 mg/Lz120 min. All the patients showed a GHRH-mediated GH peak under 4 mg/L. Acute reduction of FFA by acipimox enhanced the GHRH action, with a mean GH peak of 11.1 6 1.8 mg/L and area under the curve of 652.9 6 110.3 mg/Lz120 min (both P , 0.005). Individually analyzed after acipimox, all 14 subjects presented an enhancement in the GHRH-mediated GH peak, and 8 patients showed a response over 10 mg/L. In conclusion, acute FFA reduction by acipimox increased the GH secretion elicited by GHRH in chronic hypercortisolism. Elevated FFA may be a contributing factor to the deranged GH secretion observed in Cushing’s syndrome. (J Clin Endocrinol Metab 82: 3165– 3168, 1997)

G

FFA elevations reduce or block GH secretion stimulated by a variety of stimuli or conditions, whereas FFA reduction stimulates GH secretion (11). The recent availability of acipimox, a nicotinic acid analogue that blocks lipolysis and which is devoid of significant side effects (13, 14), provided the best tool for further understanding the role of FFA depression on GH regulation. Interestingly, acipimox-mediated FFA reduction enhances or even restores GH secretion in some pathological conditions associated with substantially reduced secretion of GH, such as obesity or aging (15–18). The aim of this study was to evaluate the effect of an acute reduction of plasma FFA by acipimox, on the GH response to GHRH in patients with Cushing’s syndrome.

LUCOCORTICOIDS inhibit somatic growth and GH secretion (1–5). Furthermore, in states of chronic hypercortisolism, such as in Cushing’s syndrome, GH secretion seems blunted in response to all stimuli so far tested (6 – 8), even when GH secretion is challenged with the most potent somatotroph stimulus so far known, i.e. combined administration of GHRH and GHRP-6 (9). The mechanisms of action by which glucocorticoids impair GH secretion in chronic hypercortisolism are unknown, and it seems reasonable that the ensuing GH deficit may contribute to some of the deleterious and hypercatabolic effects of that syndrome. On the other hand, GH secretion is closely linked to metabolic alterations, as well as to the intake of nutrients (10 –12). A classic feedback relationship has been postulated between GH and the metabolically active component of lipids, i.e. the nonesterified fatty acids, also called free fatty acids (FFA). Received February 10, 1997. Revision received May 2, 1997. Accepted May 20, 1997. Address all correspondence and requests for reprints to: F. F. Casanueva, M.D., Ph.D., PO Box 563, E-15780 Santiago de Compostela, Spain. E-mail: [email protected]. * This work was supported by a research grant from Fundacion Espan˜ola Contra el Cancer, Fundacion Salud 2000, and FIS (Spanish Ministry of Health).

Subjects and Methods Fourteen women with Cushing’s syndrome were studied. They were 43.0 6 4.3 yr old, had a body mass index (calculated as weight in Kg divided by the square of height in meters) of 37.2 6 2.5. Their 24-h free urinary cortisol was 500.9 6 92.2 mg, with IGF-I values of 202.6 6 25.9 mg/L and IGF-BP3 of 3.15 6 0.3 mg/L. Two of them had an adrenal adenoma and the rest an ACTH-secreting pituitary adenoma (Cushing’s disease). Diagnoses were established by clinical, biochemical, and image criteria, and diabetes mellitus and partial hypopituitarism were specifically ruled out. Each diagnosis was confirmed histologically after sur-

3165

3166

COMMENTS

JCE & M • 1997 Vol 82 • No 9

gery. The patients led normal life-styles and were not taking medication. Approval for this study was obtained from the Hospital Ethics Committee, and all the subjects provided informed consent. Tests were started at 0800 h, after an overnight fast, with the subjects recumbent. An indwelling catheter was placed in a forearm vein and kept patent with a slow infusion of 150 mmol/L NaCl. Each subject was tested twice on separate occasions. On one day, placebo was administered at 0800 h and 1100 h (2240 and 260 min); and then patients underwent, at 1200 h (0 min), an iv bolus injection of 100 mg GHRH (GRF 1–29 NH2, Geref, Serono, Spain). On a separate day, they received acipimox (Olbetam, Farmitalia Carlo Erba, Milan, Italy) at the dose of 250 mg po at 2240 min and again 250 mg at 260 min, followed by 100 mg iv of GHRH at 0 min. Tests were carried out single-blind and in random order, with intervals of at least 4 days. Plasma GH was measured by an immunoradiometric assay (Bio Merieux, Spain), with intraassay coefficients of variation of 5 and 5.6% and interassay coefficients of variation of 6% (1.6 mg/L) and 4.4% (19.0 mg/L). FFA were analyzed by an enzymatic method, as described (19). Samples from each patient were assayed at the same time. The data are presented and analyzed as absolute values and are shown as mean 6 se, mean GH peak, and as areas under the secretory curve (AUC). AUC were calculated by a trapezoidal method. Results were compared by a nonparametric test (Wilcoxon). Values of P , 0.05 were considered significant.

Results

As expected, GHRH-induced GH secretion in Cushing’s syndrome patients was severely blunted (Fig. 1), with a mean GH peak of 1.8 6 0.3 mg/L and AUC of 121.3 6 21.6 mg/Lz120 min. Compared with the FFA basal values of a normal women population from our laboratory (454 6 23 mmol/L), Cushing’s syndrome patients had significantly higher levels (P , 0.05) that were reduced when pretreated with acipimox. In fact, FFA levels at 0800, 1100, 1300, and 1400 h were: 814 6 61, 746 6 50, 725 6 62, and 934 6 56 mmol/L after placebo (no significant change vs. basal value) and 799 6 57, 239 6 26, 208 6 21, and 240 6 28 mmol/L after acipimox pretreatment (P , 0.05 vs. basal values). This acipimox-mediated FFA reduction did not significantly change the GH basal values, which were 0.5 6 0.2 mg/L, 0.6 6 0.1 mg/L, and 1.9 6 0.5 mg/L at 0800, 1100, and 1200 h, respectively. However, the reduction in FFA levels notably enhanced the GH secretion after the subsequent GHRH administration (Fig. 1), with a mean GH peak of 11.1 6 1.8 mg/L and AUC of 652.9 6 110.3 mg/Lz120 min (both P , 0.005 vs. placebo values). Individually analyzed (Fig. 1), all patients in the placebo pretreated group showed a GHRH-mediated GH secretion with peaks under 4 mg/L, but after reduction of FFA by acipimox, only 2 out of 14 patients had stimulated GH peaks under 4 mg/L, and 8 had responses over 10 mg/L. In all 14 patients, acipimox increased the GH response after GHRH, with respect to the placebo-GHRH test. Both the reduction in FFA levels and the increase in GH secretion after acipimox pretreatment were not correlated with any biological parameter of the subjects studied, such as age or body mass index. Two subjects experienced a mild face flushing after the first dose of acipimox. Discussion

Because Cushing’s syndrome is associated with a blunted GH secretion, with respect to all stimuli tested to date (10), a significant number of attempts have been made to understand the altered mechanisms implicated in such a secretory

FIG. 1. Upper panel, Mean 6 SE of plasma GH values after the administration on 2 separate occasions of 1 mg/kg of GHRH at 0 min, in 14 women with Cushing’s syndrome. On 1 day, patients were pretreated with placebo, and on the other, they underwent a treatment with acipimox 250 mg po at 2240 min and 250 mg po at 260 min. Lower panel, Individual GH peak in patients pretreated with placebo (open circle) or pretreated with acipimox (black arrow point). Mean 6 SE GH peak (n 5 14) in the 2 groups of treatment. **, P , 0.005.

blockade. Contrary to other pathologies associated with reduced GH release (like obesity), hypercortisolism has, until now, been resistant to any pharmacological intervention aimed at correcting the problem. In fact, suppression of endogenous SRIH secretion, repetitive priming with GHRH, hypothalamic stimulation, or administration of GH secretagogues have all failed to minimally increase the blunted hormone release in man (20 –23). Furthermore, the combined administration of GHRH plus GHRP-6, the most potent GH releaser to date with capacity to restore GH release in late

COMMENTS

adulthood or in obesity (24 –26), failed to change the GH secretion in Cushing’s syndrome (9). These results suggest that the GH blockade observed in obesity or aging are functional and potentially reversible by pharmacological treatment. On the contrary, it indicates that glucocorticoids exert a permanent inhibition or damage upon somatotroph cells that is not reversible by acute interventions. The inhibitory action ceases when hypercortisolism is eliminated by surgery, although it takes considerable time before normal GH secretion advents (27). In the present work, the acute reduction of FFA by acipimox administration enhanced GHRH-mediated GH discharge in all patients with Cushing’s syndrome, and 8 out of 14 patients showed a response after GHRH over 10 mg/L. Cushing’s syndrome may then be added to the list of states associated with diminished GH release in which a previous FFA reduction enhances GH discharge, such as obesity, hyperthyroidism, or aging (15–18, 28). This fact is relevant because it is the first pharmacological intervention that results in an increase in GH levels in chronic hypercortisolism, More controversial is the point of action and mechanism by which FFA reduction enhances GH secretion. There is now compelling evidence indicating that FFA modulation of GH secretion is exerted at the pituitary level, probably by direct action on the somatotroph function (29 –31). It has been shown that extracellular increase in FFA may alter several intracellular signaling systems in pituitary somatotrophs, leading to a reduction in GH secretion (32–34). Although direct evidence is lacking, our working hypothesis is that FFA reduction also must be operating at the somatotroph level, through a mechanism that still remains undefined. In support of this hypothesis comes the observation that acipimox induced-FFA reduction leads to a fixed increase in GH secretion that is additive to any stimuli chosen, either acting at the hypothalamus or at a pituitary level (16, 17). In the present work, it has been shown that acute reduction of FFA practically normalizes the GHRH-mediated GH release in Cushing’s syndrome patients, an action that is not attributed to acipimox per se but to FFA reduction (35). However, the response to acipimox-GHRH in Cushing’s syndrome patients was still lower than that of normal subjects challenged with the same stimuli (16), suggesting that the elevated FFA levels may be a contributory factor, but not the only one, to the impeded GH secretion in hypercortisolism. Considerable work is necessary to fully understand the mechanisms by which glucocorticoid excess leads to a semichronic inactivation of the somatotroph function. In conclusion, the reduction of FFA by acipimox enhanced GHRH-induced GH secretion in all patients with Cushing’s syndrome. Elevated FFA may be a contributing factor for the altered GH secretion in chronic hypercortisolism. Acknowledgments The expert technical help of Ms. Mary Lage is gratefully acknowledged.

References 1. Boldgett FM, Burgin L, Iezzoni D, Gribetz D, Talbot ND. 1956 Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. N Eng J Med. 254:636 – 640.

3167

2. Hartog M, Gaafar MA, Fraser R. 1964 Effects of corticosteroids on serum growth hormone. Lancet i:376 –378. 3. Frantz AG, Rabkin MT. 1964 Human growth hormone: clinical measurement, response to hypoglycemia and suppression by corticosteroids. N Eng J Med. 271:1375–1381. 4. Krieger DT, Glick SM. 1972 Growth hormone and cortisone responsiveness in Cushing’s syndrome: relation to a possible central nervous system etiology. Am J Med. 52:25– 40. 5. Nakagawa K, Horiuchi Y, Mashimo K. 1969 Responses of plasma growth hormone and corticosteroids to insulin and arginine with or without prior administration of dexamethasone. J Clin Endocrinol Metab. 29:35– 40. 6. Smals AEM, Pieters GFFM, Smals AG, Benraad T, Kloppenborg P. 1986 Human pancreatic growth hormone releasing hormone fails to stimulate human growth hormone both in Cushing’s disease and in Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf). 24:401– 407. 7. Demura R, Demura H, Nunokawa T, Baba H, Miura K. 1972 Responses of plasma ACTH, GH, LH and 11-hydroxycorticosteroids to various stimuli in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 34:852– 859. 8. Dieguez C, Page MD, Scanlon MF. 1988 Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol (Oxf). 28:109 –143. 9. Leal-Cerro A, Pumar A, Garcia E, Dieguez C, Casanueva FF. 1994 Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 41:649 – 654. 10. Casanueva FF. 1992 Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am. 21:483–517. 11. Dieguez C, Casanueva FF. 1995 Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab. 6:55–59. 12. Vance ML. 1993 Metabolic status and growth hormone secretion in man. J Pediatr Endocrinol. 6:3– 4. 13. Pontiroli AE, Lanzi R, Monti LD, Pozza G. 1990 Effect of acipimox, a lipid lowering drug on growth hormone (GH) response to GH-releasing hormone in normal subjects. J Endocrinol Invest. 13:539 –542. 14. Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G. 1991 Growth hormone (GH) auto feedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 72:492– 495. 15. Lee EJ, Nam SY, Kima KR, et al. 1995 Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects. J Clin Endocrinol Metab. 80:2495–2498. 16. Peino R, Cordido F, Pen˜alva A, Alvarez CV, Dieguez C, Casanueva FF. 1996 Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli. J Clin Endocrinol Metab. 81:909 –913. 17. Cordido F, Peino R, Pen˜alva A, Alvarez CV, Casanueva FF, Dieguez C. 1996 Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab. 81:914 –918. 18. Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R. 1996 Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids. J Clin Endocrinol Metab 81:3998 – 4001. 19. Okabe H, Uji Y, Nagashima K, Noma A. 1980 Enzymatic determination of free fatty acids in serum. Clin Chem. 26:1540 –1543. 20. Veldhuis JD, Lizarralde A, Iranmanesh A. 1992 Divergent effects of shortterm glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. J Clin Endocrinol Metab. 74:96 –102. 21. von Werder K, Hane S, Forsham PH. 1971 Suppression of the hypothalamo pituitary-adrenal axis and growth hormone release with dexamethasone. Horm Metab Res. 3:171–174. 22. Leal A, Pereira JL, Garcia-Luna PP, et al. 1990 Effect of the enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 33:291–295. 23. Leal A, Pumar A, Villamil F, Astorga R, Dieguez C, Casanueva FF. 1993 Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 38:399 – 403. 24. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. 1990 Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 70:975–982. 25. Cordido F, Pen˜alva A, Dieguez C, Casanueva FF. 1993 Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6:Evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 76:819 – 823. 26. Alster DK, Bowers CY, Jaffe CA, Ho PJ, Barkan AL. 1993 The growth hormone (GH) response to GH-releasing peptide (His-D Trp-Ala-Trp-D Phe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly. J Clin Endocrinol Metab. 77:842– 845. 27. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. 1994 Suppressed spontaneous and stimulated growth hormone secretion in patients

3168

28. 29. 30.

31.

COMMENTS

with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab. 78:131–137. Lee EJ, Kim KR, Lee HC, et al. 1995 Acipimox potentiates growth hormone response to growth hormone releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism. Metabolism. 44:1509 –1512. Casanueva FF, Villanueva L, Dieguez C, et al. 1987 Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab. 65:634 – 642. Alvarez CV, Mallo F, Burguera B, Cacicedo L, Dieguez C, Casanueva FF. 1991 Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing factor in the rat. Neuroendocrinology. 53:185–189. Casabiell X, Zugaza JL, Pombo CM, Pandiella A, Casanueva FF. 1993 Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. Exp Cell Res. 205:365–373.

JCE & M • 1997 Vol 82 • No 9

32. Renier G, Abribat T, Brazeau P, Deslauriers N, Gaudreau P. 1990 Cellular mechanism of caprylic acid-induced growth hormone suppression. Metabolism. 39:1108 –1112. 33. Zugaza JL, Casabiell X, Bokser L, Casanueva FF. 1995 Oleic acid blocks EGF-induced Ca21i release without altering cellular metabolism in fibroblast EGFR T17. Biochem Biophys Res Commun. 207:105–110. 34. Perez FR, Casabiell X, Camin˜a JP, Zugaza JL, Casanueva FF. 1997 cisunsaturated free fatty acids block growth hormone and prolactin secretion in thyrotropin-releasing hormone-stimulated GH3 cells by perturbing the function of plasma membrane integral proteins. Endocrinology. 138:264 –272. 35. Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KGMM. 1993 Acipimox increases glucose disposal in normal men independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism. 42:308 –314.